Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase <scp>II</scp> trial
Yawen Wang(Sun Yat-sen University), Hong‐Wei Xue(South China Agricultural University), Liqun Zou(Sichuan University), Qingqing Cai(Sun Yat-sen University), Xiuhua Sun(Dalian Medical University), Wei Song(Qingdao University), Mingzhi Zhang(Chinese Academy of Sciences), Lili Wang(Qingdao University), Liling Zhang(Union Hospital), Huilai Zhang(Shanxi Medical University)
Cited by 40
Related Papers
LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment
|Nature Communications|2018|525
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250